Initial update for NKX019 in multiple autoimmune indications expected in second half of 2025Cash balance of $334.0 million on June 30, 2025, including cash, cash equivalents and investments, expected ...

Novartis announces positive results from VAYHIT2 phase III trial of ianalumab plus eltrombopag in patients with primary immune thrombocytopenia: Basel Wednesday, August 13, 2025, ...

Topline results from pivotal Phase 3 INDIGO trial in Immunoglobulin G4-Related Disease expected around year-end 2025 - ...

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that causes the gradual loss of motor neurons in the brain and spinal cord, leading to muscle weakness, paralysis, and ...

Unexplained tingling, known to doctors as paresthesia, is often only temporary and harmless. But it can be a symptom of ...

In a comprehensive study, researchers from the Department of Epidemiology at the Faculty of Medicine at the University of ...

Former Teva North America CEO Sven Dethlefs, PhD, to lead Celea PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated ...

FDA Approves Tiziana Life Sciences Phase 2 IND for Multiple System AtrophyNEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a ...

Adicet Bio (NASDAQ:ACET), a biotechnology company focused on gamma delta T cell therapies for autoimmune diseases and cancer, reported its second quarter 2025 earnings on August 7 ...

Company reports Q2 2025 AUCATZYL® net product revenue of $20.9 million and $29.9 for the first six months of 2025Company recently received conditional marketing authorization from U.K. Medicines and ...

Zenas BioPharma, Inc. ( ($ZBIO) ) has released its Q2 earnings. Here is a breakdown of the information Zenas BioPharma, Inc. presented to its ...

Autolus Therapeutics ( ($AUTL) ) has released its Q2 earnings. Here is a breakdown of the information Autolus Therapeutics presented to its ...